Core Viewpoint - Boston Scientific (BSX) has been a highly searched stock recently, indicating potential investor interest and market activity [1] Earnings Estimate Revisions - For the current quarter, Boston Scientific is expected to report earnings of $0.72 per share, reflecting a year-over-year increase of +16.1% [5] - The Zacks Consensus Estimate for the current fiscal year is $2.91, indicating a year-over-year change of +15.9%, with a +2.2% revision over the last 30 days [5] - The consensus earnings estimate for the next fiscal year is $3.26, showing a change of +11.8% from the previous year, with a +0.9% revision over the past month [6] - Boston Scientific holds a Zacks Rank 2 (Buy), suggesting a favorable outlook based on recent earnings estimate changes [7] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $4.89 billion, indicating a year-over-year increase of +18.6% [11] - For the current fiscal year, the sales estimate is $19.49 billion, reflecting a change of +16.4%, while the next fiscal year's estimate is $21.55 billion, indicating a +10.6% change [11] Last Reported Results and Surprise History - In the last reported quarter, Boston Scientific achieved revenues of $4.66 billion, a year-over-year increase of +20.9%, and an EPS of $0.75 compared to $0.56 a year ago [12] - The company exceeded the Zacks Consensus Estimate for revenues by +2.31% and for EPS by +11.94% [12] - Boston Scientific has consistently beaten consensus EPS and revenue estimates over the past four quarters [13] Valuation - Boston Scientific is graded D on the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [17] - Valuation metrics such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for assessing whether the stock is overvalued, fairly valued, or undervalued [15][16] Bottom Line - The information presented suggests that Boston Scientific may outperform the broader market in the near term, supported by its Zacks Rank 2 [18]

Core Viewpoint - Arch Capital Group (ACGL) has been a highly searched stock recently, indicating potential investor interest and market activity [1] Earnings Estimates - Arch Capital is expected to report earnings of $2.34 per share for the current quarter, reflecting a year-over-year decline of 9% [5] - The consensus earnings estimate for the current fiscal year is $7.89, indicating a year-over-year decrease of 15% [5] - For the next fiscal year, the consensus earnings estimate is $9.57, showing a year-over-year increase of 21.2% [6] - Over the last 30 days, the earnings estimates have seen slight changes of -1.8% for the current quarter and -0.1% for the current fiscal year [5][6] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $4.68 billion, representing a year-over-year increase of 18.8% [11] - For the current fiscal year, the revenue estimate is $18.91 billion, indicating a growth of 13.8%, while the next fiscal year is projected at $20.32 billion, reflecting a growth of 7.5% [11] Last Reported Results and Surprise History - In the last reported quarter, Arch Capital achieved revenues of $4.56 billion, a year-over-year increase of 21.3% [12] - The EPS for the same period was $1.54, down from $2.45 a year ago, with a surprise of +12.41% compared to the consensus estimate [12][13] - The company has consistently beaten consensus EPS estimates in the last four quarters and topped revenue estimates three times [13] Valuation - Arch Capital has a Zacks Rank of 3 (Hold), suggesting it may perform in line with the broader market in the near term [7][18] - The Zacks Value Style Score for Arch Capital is graded B, indicating it is trading at a discount compared to its peers [17]

Core Viewpoint - Novo Nordisk's stock has experienced a decline of -2.2% over the past month, underperforming the Zacks S&P 500 composite's -0.5% change and the Zacks Large Cap Pharmaceuticals industry's -2% loss, raising questions about its near-term performance [1] Earnings Estimate Revisions - The consensus earnings estimate for the current quarter is $0.91 per share, reflecting a year-over-year increase of +9.6%, with a recent change of +2.2% over the last 30 days [4] - For the current fiscal year, the consensus earnings estimate is $3.85, indicating a +17.4% change from the previous year, with a +1.3% change in the last 30 days [4] - The next fiscal year's consensus earnings estimate is $4.71, showing a +22.4% change from the prior year, with a +2.1% change over the past month [5] - Novo Nordisk holds a Zacks Rank 3 (Hold), influenced by recent changes in consensus estimates and other earnings-related factors [6] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $11.33 billion, indicating a year-over-year increase of +19.1% [10] - The sales estimates for the current and next fiscal years are $50.66 billion and $58.15 billion, reflecting changes of +20.3% and +14.8%, respectively [10] Last Reported Results and Surprise History - In the last reported quarter, Novo Nordisk achieved revenues of $12.26 billion, a year-over-year increase of +28.9%, and an EPS of $0.91 compared to $0.71 a year ago [11] - The reported revenues exceeded the Zacks Consensus Estimate of $11.34 billion by +8.11%, and the EPS surprise was +9.64% [11] - Over the last four quarters, Novo Nordisk surpassed consensus EPS estimates twice and revenue estimates twice [12] Valuation - Novo Nordisk is graded B in the Zacks Value Style Score, indicating it is trading at a discount to its peers [16]

Core Viewpoint - Costco has been trending positively in the stock market, outperforming the S&P 500 and the discount retail industry, raising questions about its future stock performance [1] Earnings Estimate Revisions - The current quarter's earnings estimate for Costco is $4.25 per share, reflecting a year-over-year increase of +12.4% with a recent change of +0.5% in the consensus estimate [4] - For the current fiscal year, the consensus earnings estimate is $17.96, indicating a change of +11.5% from the previous year, with a slight change of +0.1% over the last 30 days [4] - The next fiscal year's consensus earnings estimate stands at $19.73, showing a change of +9.9% from the prior year, with no change in the estimate over the past month [5] Revenue Growth Forecast - Costco's consensus sales estimate for the current quarter is $63 billion, representing a year-over-year change of +7.7% [10] - The sales estimates for the current and next fiscal years are $274.3 billion and $292.89 billion, indicating changes of +7.8% and +6.8%, respectively [10] Last Reported Results and Surprise History - In the last reported quarter, Costco achieved revenues of $63.72 billion, a year-over-year increase of +9%, with an EPS of $4.02 compared to $3.71 a year ago [11] - The reported revenues exceeded the Zacks Consensus Estimate of $63.22 billion by +0.79%, while the EPS fell short by -1.71% [11] - Over the last four quarters, Costco surpassed consensus EPS estimates three times and revenue estimates two times [12] Valuation - Costco is graded D in the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [16] - Valuation multiples such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for assessing whether Costco's stock is overvalued or undervalued [14][15] Bottom Line - The information presented may assist in evaluating the market interest surrounding Costco, with a Zacks Rank of 3 suggesting it may perform in line with the broader market in the near term [17]

Core Viewpoint - Analog Devices (ADI) has shown a strong performance recently, with a +7.1% return over the past month, contrasting with the S&P 500's -0.5% and the Zacks Semiconductor - Analog and Mixed industry's -2.5% [2] Earnings Estimate Revisions - For the current quarter, Analog Devices is expected to report earnings of $1.69 per share, reflecting a +20.7% change year-over-year, with the consensus estimate remaining unchanged over the last 30 days [5] - The consensus earnings estimate for the current fiscal year is $7.11, indicating a +11.4% change from the previous year, also unchanged over the last month [5] - For the next fiscal year, the consensus estimate is $8.61, representing a +21.1% change from the prior year, with no changes in the estimate over the past month [6] - The Zacks Rank for Analog Devices is 3 (Hold), indicating a neutral outlook based on recent earnings estimate changes and other related factors [7] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $2.5 billion, which indicates a +15.9% year-over-year change [11] - For the current fiscal year, the sales estimate is $10.27 billion, reflecting a +9% change, while the next fiscal year's estimate is $11.47 billion, indicating a +11.7% change [11] Last Reported Results and Surprise History - In the last reported quarter, Analog Devices generated revenues of $2.42 billion, a -3.6% change year-over-year, with an EPS of $1.63 compared to $1.73 a year ago [12] - The reported revenues exceeded the Zacks Consensus Estimate of $2.36 billion by +2.79%, and the EPS surprise was +5.84% [12] - The company has consistently beaten consensus EPS and revenue estimates in the trailing four quarters [13] Valuation - Analog Devices is graded D in the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [17]

Core Viewpoint - PepsiCo has been experiencing a decline in stock performance, with a return of -9.1% over the past month, significantly underperforming the S&P 500 composite's -0.7% change and the Zacks Beverages - Soft drinks industry's -1.4% loss [2] Earnings Estimates Revisions - For the current quarter, PepsiCo is expected to report earnings of $2.08 per share, reflecting an -8.8% change from the previous year, with the Zacks Consensus Estimate decreasing by -10.4% over the last 30 days [5] - The consensus earnings estimate for the current fiscal year is $7.93, indicating a -2.8% change from the prior year, with a -4.8% revision in the last month [5] - For the next fiscal year, the consensus estimate is $8.39, showing a +5.8% change from the previous year, although this estimate has also changed by -4.8% recently [6] - PepsiCo holds a Zacks Rank 4 (Sell) due to significant changes in earnings estimates and other related factors [7] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $22.39 billion, indicating a -0.5% year-over-year change [11] - For the current fiscal year, the sales estimate is $92.22 billion, reflecting a +0.4% change, while the next fiscal year's estimate is $95.28 billion, indicating a +3.3% change [11] Last Reported Results and Surprise History - In the last reported quarter, PepsiCo's revenues were $17.92 billion, down -1.8% year-over-year, with an EPS of $1.48 compared to $1.61 a year ago [12] - The reported revenues exceeded the Zacks Consensus Estimate of $17.75 billion by +0.94%, while the EPS fell short by -1.33% [12] - Over the last four quarters, PepsiCo surpassed consensus EPS estimates three times but only exceeded revenue estimates once [13] Valuation - PepsiCo's valuation metrics indicate that it is trading at a premium to its peers, receiving a Zacks Value Style Score of D, suggesting it may be overvalued [17]

Core Viewpoint - Adma Biologics has shown strong stock performance recently, with a +17.7% return over the past month, contrasting with the S&P 500's -0.7% change, indicating potential investor interest and market momentum [2]. Earnings Estimate Revisions - The consensus earnings estimate for Adma Biologics is $0.16 per share for the current quarter, reflecting a year-over-year increase of +100% [5]. - For the current fiscal year, the consensus earnings estimate stands at $0.71, indicating a year-over-year change of +44.9% [5]. - The next fiscal year's consensus earnings estimate is $0.93, representing a +31% change from the previous year [6]. - The Zacks Rank for Adma Biologics is 2 (Buy), suggesting a favorable outlook based on earnings estimate revisions [7]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $119.1 million, indicating a year-over-year increase of +45.5% [11]. - For the current fiscal year, the sales estimate is $495.8 million, reflecting a +16.3% change, while the next fiscal year's estimate is $611.5 million, indicating a +23.3% change [11]. Last Reported Results and Surprise History - In the last reported quarter, Adma Biologics generated revenues of $117.55 million, a year-over-year increase of +59.1% [12]. - The EPS for the same period was $0.14, compared to $0.04 a year ago, with a revenue surprise of +4.77% against the Zacks Consensus Estimate [12]. - Over the last four quarters, the company has surpassed consensus EPS estimates three times and topped revenue estimates each time [13]. Valuation - Adma Biologics has a Zacks Value Style Score of D, indicating it is trading at a premium compared to its peers [17].

Core Viewpoint - Gilead Sciences has experienced a decline in stock performance recently, and various factors, including earnings estimates and revenue growth, will influence its future stock trajectory [2][5][11]. Earnings Estimate Revisions - Gilead is projected to report earnings of $1.99 per share for the current quarter, reflecting a year-over-year decrease of 1% [5]. - The consensus earnings estimate for the current fiscal year is $7.91, indicating a significant year-over-year increase of 71.2% [5]. - For the next fiscal year, the consensus estimate is $8.39, representing a year-over-year growth of 6.1% [6]. - The Zacks Rank for Gilead is 3 (Hold), indicating a neutral outlook based on recent earnings estimate revisions [7]. Revenue Growth Forecast - The consensus sales estimate for Gilead in the current quarter is $7 billion, showing a year-over-year increase of 0.6% [11]. - Revenue estimates for the current and next fiscal years are $28.51 billion (a decrease of 0.8%) and $29.78 billion (an increase of 4.5%), respectively [11]. Last Reported Results and Surprise History - Gilead reported revenues of $6.67 billion in the last quarter, which is a year-over-year decline of 0.3% [12]. - The EPS for the last reported quarter was $1.81, compared to -$1.32 a year ago, with a revenue surprise of -2.46% and an EPS surprise of -0.55% [12]. - Over the last four quarters, Gilead has surpassed consensus EPS estimates three times and revenue estimates three times [13]. Valuation - Gilead's valuation metrics, including price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), are essential for assessing whether the stock is fairly valued [14][15]. - The Zacks Value Style Score for Gilead is graded B, indicating that the stock is trading at a discount compared to its peers [17].

GE Vernova (GEV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this the energy business spun off from General Electric have returned +21.2% over the past month versus the Zacks S&P 500 composite's -0.8% change. The Zacks Alternative Energy - Other industry, to which GE Vernova belongs, has gained 2.8% over this period. Now the key question is: Where could the stock ...

Grab Holdings Limited (GRAB) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this company have returned -2.5% over the past month versus the Zacks S&P 500 composite's -4.8% change. The Zacks Internet - Software industry, to which Grab belongs, has lost 9.1% over this period. Now the key question is: Where could the stock be headed in the near term?Althoug ...